Feeling sleepy during the day may trigger Alzheimer’s: Researchers

New York: In a significant finding, Johns Hopkins researchers have revealed that those who feel sleepy during the day are nearly three times more likely to develop Alzheimer’s disease than those who have a good night’s sleep.

An analysis of data captured during a long-term study of ageing adults showed that those who report being very sleepy during the day were nearly three times more likely than those who didn’t to have brain deposits of beta amyloid — a protein that’s a hallmark for Alzheimer’s disease — years later.

The finding, reported in the journal SLEEP, adds to a growing body of evidence that poor quality sleep could encourage this form of dementia to develop, suggesting that getting adequate night-time sleep could be a way to help prevent Alzheimer’s disease.

“Factors like diet, exercise and cognitive activity have been widely recognised as important potential targets for Alzheimer’s disease prevention, but sleep hasn’t quite risen to that status — although that may well be changing,” said Adam P. Spira, Associate Professor at the Johns Hopkins’ Bloomberg School of Public Health.

Spira led the study with collaborators from the National Institute on Aging (NIA), the Bloomberg School and Johns Hopkins Medicine.

“If disturbed sleep contributes to Alzheimer’s disease, we may be able to treat patients with sleep issues to avoid these negative outcomes,” Spira added.

The study used data from the Baltimore Longitudinal Study of Aging (BLSA) — a long-term study started by the NIA in 1958 that followed the health of thousands of volunteers as they age.

Before adjusting for demographic factors that could influence daytime sleepiness, the results showed that those who reported daytime sleepiness were about three times more likely to have beta-amyloid deposition than those who didn’t report daytime fatigue.

After adjusting for these factors, the risk was still 2.75 times higher in those with daytime sleepiness.

The unadjusted risk for amyloid-beta deposition was about twice as high in volunteers who reported napping, but this did not reach statistical significance.

It’s currently unclear why daytime sleepiness would be correlated with the deposition of beta-amyloid protein, Spira said.

One possibility is that daytime sleepiness itself might somehow cause this protein to form in the brain.

Based on previous research, a more likely explanation is that disturbed or insufficient sleep due to other factors, causes beta-amyloid plaques to form through a currently unknown mechanism, and that these sleep disturbances also cause excessive daytime sleepiness.

“However, we cannot rule out that amyloid plaques that were present at the time of sleep assessment caused the sleepiness,” added the researchers.

  • Related Posts

    • Health
    • February 10, 2024
    • 26 views
    Appointment of CEO packs a Punch in NeuroEqulibrium’s Global Goal

    New Delhi: The ambition of NeuroEquilibrium gets a shot in the arm with the appointment of industry vetran Samit Verma as its CEO (Chief Executive Officer). Its global aspiration will…

    Millets reigned Supreme in International Symposium on Gut Health

    New Delhi: Millets reign supreme as gut health assumes most important aspect of the latest preventive and curative healthcare approach. This fact was writ large on Symposium on ‘Gut Health…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DCA Raids Two Illegal Pharmacies; Seizes Stocks Of Over 60 Types Of Drugs

    DCA Raids Two Illegal Pharmacies; Seizes Stocks Of Over 60 Types Of Drugs

    Ramdev, Balkrishna Acharya Ready For ‘Public Apology’; Supreme Court Next Hearing On April 23

    Ramdev, Balkrishna Acharya Ready For ‘Public Apology’; Supreme Court Next Hearing On April 23

    Organovo’s Drug Significantly Reduces Liver Fat In NASH Study

    Organovo’s Drug Significantly Reduces Liver Fat In NASH Study

    Significant Decline In Pharma Deals In Q1

    Significant Decline In Pharma Deals In Q1

    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    Rise In AMR Is Leaving Doctors With Fewer Options In Drugs

    CDSCO Releases Draft Guidance To Align New Drugs And Clinical Trials Rules And SUGAM For Stakeholder’s Comments

    CDSCO Releases Draft Guidance To Align New Drugs And Clinical Trials Rules And SUGAM For Stakeholder’s Comments